Articles by Brandon Twyford
About 40% of patients on AI + palbociclib developed ESR1 mutations in PADA-1, emerging as early as 6 months into treatment.
Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial.
Dual immunotherapy plus trastuzumab shows activity in ER+ or PD-L1+ trastuzumab-resistant HER2+ breast cancer.
Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
Palbociclib rechallenge did not significantly improve PFS in HR+/HER2- advanced breast cancer, PALMIRA trial finds.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
The study shows the prognostic value of ctDNA in detecting MRD in patients with stage II/III CRC.
Trial results show no significant benefit of adding chemoradiation to adjuvant chemotherapy in resected gallbladder cancer.
SBRT shows promise for liver tumor control, but hepatobiliary toxicity remains a concern.
Atezolizumab plus bevacizumab shows promising efficacy and tolerability for advanced HCC with Child-Pugh B cirrhosis.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.